Meeting
2023 ASCO Annual Meeting
Tumor-informed circulating tumor DNA (TI-ctDNA) based molecular residual disease (MRD) detection and relapse risk for patients with stage II-IV melanoma in surgical remission: A single center experience.
Authors
Logan Rhea
Virginia Commonwealth University Health System, Richmond, VA
Logan Rhea , Megan Daniels , Roy Sabo , Andrew Stewart Poklepovic
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9572)
DOI
10.1200/JCO.2023.41.16_suppl.9572
Abstract #
9572
Poster Bd #
335
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Utilization of tumor-informed circulating tumor DNA in detecting minimal residual disease and guiding adjuvant therapy in liver cancer.
First Author: De-Zhen Guo
Poster
2024 ASCO Annual Meeting
Real-world ctDNA testing patterns, associated biomarkers and sites of metastasis in early stage colorectal cancer.
First Author: Erin Fidyk
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Prognostic value of minimal residual disease profiling in resectable hepatocellular carcinoma.
First Author: Jie Hu
Poster
2023 ASCO Annual Meeting
Dynamic ctDNA to inform the precise management of resected NSCLC: LUNGCA-2 study.
First Author: Liang Xia